Who are Aranesp® (darbepoetin alfa)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epogen, ARM B: IV iron + epoietin zeta sequence, Epoetin β (450 UI/kg/week), Vifor and EPO, continuation (darbepoetinum), epoetin beta [NeoRecormon].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aranesp-darbepoetin-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Aranesp® (darbepoetin alfa) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aranesp® (darbepoetin alfa) (Aranesp® (darbepoetin alfa)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent (ESA). Area: Hematology/Oncology.

phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Aranesp® (darbepoetin alfa) (Aranesp® (darbepoetin alfa)) — Amgen. Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aranesp® (darbepoetin alfa) TARGET	Aranesp® (darbepoetin alfa)	Amgen	phase 3	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
Epogen	Epoetin Alfa-Epbx	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor	1989-01-01
ARM B: IV iron + epoietin zeta sequence	ARM B: IV iron + epoietin zeta sequence	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
Epoetin β (450 UI/kg/week)	Epoetin β (450 UI/kg/week)	Germans Trias i Pujol Hospital	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
Vifor and EPO	Vifor and EPO	Kunshan First People's Hospital Affiliated to Jiangsu University	marketed	Iron replacement agent and erythropoiesis-stimulating agent (ESA)	Iron (ferric ion) and erythropoietin receptor (EPOR)
continuation (darbepoetinum)	continuation (darbepoetinum)	Anemia Working Group Romania	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
epoetin beta [NeoRecormon]	epoetin beta [NeoRecormon]	Hoffmann-La Roche	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent (ESA) class)

Amgen · 4 drugs in this class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 3 drugs in this class
Hospital de Clinicas de Porto Alegre · 2 drugs in this class
Pfizer · 2 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Chong Kun Dang Pharmaceutical · 2 drugs in this class
Barts & The London NHS Trust · 1 drug in this class
Australian and New Zealand Intensive Care Research Centre · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Biocad · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aranesp® (darbepoetin alfa) — Competitive Intelligence Brief. https://druglandscape.com/ci/aranesp-darbepoetin-alfa. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab